Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
4.950
-0.120 (-2.37%)
At close: Dec 20, 2024, 4:00 PM
4.990
+0.040 (0.81%)
After-hours: Dec 20, 2024, 5:47 PM EST
Sagimet Biosciences Revenue
In the year 2023, Sagimet Biosciences had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
159.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nanobiotix | 45.22M |
Cellectis | 36.04M |
scPharmaceuticals | 30.28M |
Caribou Biosciences | 11.48M |
TScan Therapeutics | 9.36M |
Checkpoint Therapeutics | 47.00K |
SGMT News
- 5 weeks ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha
- 5 weeks ago - Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne - PRNewsWire
- 2 months ago - Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
- 2 months ago - Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 2 months ago - Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewsWire
- 2 months ago - Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - GlobeNewsWire
- 5 months ago - Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors - GlobeNewsWire